Cannabicyclohexanol

Cannabicyclohexanol (also known as CP 47,497-C8 or CP 47,497 homologue) is a synthetic cannabinoid that mimics the effects of natural cannabinoids found in cannabis. It is one of the cannabinoids responsible for the psychoactive effects of cannabis.

History

Cannabicyclohexanol was first synthesized in the mid-1970s by the pharmaceutical company Pfizer. It was developed as part of a research program to find cannabinoid analogues that could be used for therapeutic purposes. However, it was never marketed as a drug and its potential medical uses remain largely unexplored.

Chemistry

Cannabicyclohexanol is a synthetic cannabinoid, which means it is a man-made chemical that is similar in structure to the natural cannabinoids found in cannabis. It is a homologue of CP 47,497, a compound that was also developed by Pfizer. The "C8" in its name refers to the eight-carbon chain that connects the two cyclohexanol rings in its structure.

Effects

Like other synthetic cannabinoids, cannabicyclohexanol binds to the same receptors in the brain as THC, the main psychoactive compound in cannabis. This means it can produce similar effects, including feelings of euphoria, altered perception, and increased appetite. However, because it is a synthetic compound, its effects can be much stronger and more unpredictable than those of natural cannabinoids.

Legal status

Cannabicyclohexanol is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act. This means it is illegal to manufacture, distribute, or possess without a license.

See also

• Cannabinoid
• Synthetic cannabinoids
• Cannabis (drug)

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia